Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends - Top-Institutions - MDSpire

Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends

  • By

  • Danh T. Tran

  • Ruyun Jin

  • Hong Zhu

  • Gabrielle Schmidt

  • Stephen R. Spellman

  • Karen K. Ballen

  • August 18, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematopoietic Cell Transplantation
    • Hematology
    • Oncology

  • #2

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Hematopoietic Cell Transplantation
    • Hematology
    • Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematopoietic Cell Transplantation
    • Hematology
    • Oncology

  • #4

    University of Minnesota Medical Center
    University of Minnesota Medical Center

    Minneapolis, MN

    Key Differentiators

    • Hematopoietic Cell Transplantation
    • Hematology
    • Oncology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematopoietic Cell Transplantation
    • Hematology
    • Oncology

Original Source(s)

Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends

  • by Danh T. Tran, Ruyun Jin, Hong Zhu, Gabrielle Schmidt, Stephen R. Spellman, Karen K. Ballen

  • August 18, 2025

Related Content

Anatomy-aware lymphoma lesion detection in whole-body PET/CT

Smarter Digital Morphology Triage

A diffusion-based approach aims to handle domain shifts, slide variability, and rare cell appearances

  • January 30, 2026

  • 3 min
Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma